肝癌的CIK细胞免疫治疗研究进展

马学斌; 马骢

肝癌的CIK细胞免疫治疗研究进展

马学斌,
马骢

海军总医院检验科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3810
- HTML全文浏览量: 10
- PDF下载量: 813
- 被引次数: 0
出版历程
- 出版日期: 2010-06-20

Research on the progress of CIK immunotherapy on liver cancer

Ma XueBin,
Ma Cong

摘要

摘要: 肝癌在全球肿瘤相关疾病中的死因占第二位,常规方法对其治疗效果并不理想,因此急需寻找新的有效方法来治疗。细胞因子激活的杀伤细胞是一种新型的免疫效应细胞,对肿瘤细胞的杀伤具有T淋巴细胞的高效性和NK细胞的非MHC限制性的特点,是目前对肝癌过继免疫治疗的有效方法之一。本文从细胞因子激活的杀伤细胞的扩增培养方法及研究进展、不同细胞因子及作用途径对其活性的影响、在杀伤肿瘤细胞中的作用机理及在肝癌治疗的实验研究与临床应用等方面进行了综述。
- 肝癌 /
- 细胞因子激活的杀伤细胞 /
- 免疫治疗
Abstract: Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide and the result of the conventional treatment was not as effective, so demand for the effective treatment options are increasing.Cytokine induced killer (CIK) cells are a new kind of immunocyte, which could act as antitumor with high efficiency of killer activity of T lymphocytes and the non-MHC restricted character of NK markers.Adoptive immunotherapy with CIK cells might represent an effective alternative to classic application for Hepatic carcinomas.This article reviews the new research progress on Cytokine induced killer cells, the effects of killer cells activity intervened by variety of cytokines and different pathways, the mechanisms of the killing and the pre-clinical and clinical research on cytokine-induced killer (CIK) cells.
- liver cancer /
- cytokine induced killer /
- immunotherapy

HTML全文

参考文献(30)

[1]Schmidt-Wolf IG, Lefterova P, Johnston V, et al.Propagation of large numbers of T cells with natural killer cell markers[J].Br J Haematol, 1994, 87 (3) ∶453-458.

[2]Wang FS, Liu MX, Zhang B, et al.Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo[J].World J Gastroenterol, 2002, 8 (3) ∶464-468.

[3]Schmidt-Wolf IG, Negrin RS, Kiem HP, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J].J Exp Med, 1991, 174 (1) ∶139-149.

[4]黎阳, 黄绍良, 魏菁, 等.不同细胞因子诱导脐血来源的CIK、NK细胞对K562细胞杀伤活性的研究[J].中国免疫学杂志, 2005, 21 (9) ∶670-673.

[5]秦莉, 王志华, 袁玉涛.IL-12对CIK细胞体外增值及细胞毒活性影响的研究[J].国际免疫学杂志, 2007, 30 (4) ∶203207.

[6]赵明峰, 邓琦, 李玉明, 等.人源白细胞介素21对外周血及脐血来源CIK细胞产生和抗肿瘤活性的作用研究[J].中国免疫学杂志, 2008, 24 (9) ∶794-799.

[7]任玮, 王志华.重组人纤维蛋白片段诱导CIK的增值及对肺癌耐顺铂细胞的杀伤作用[J].生物工程学报, 2008, 24 (8) ∶1373-1380.

[8]Marten A, Schottker B, Ziske C, et al.Increase of the immunostimulatory effect of dendritic cells by pulsing with CA199protein[J].J Immunother, 2000, 23 (4) ∶464-472.

[9]Wei XC, Zhai XH, Han XR, et al.Biological Activity of DC-CIK Cells and Its Effect Against Leukemia Cells In Vitro[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2008, 16 (5) ∶1150-1153.

[10]Joshi PS, Liu JQ, Wang Y, et al.Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin dependent mechanisms[J].J Leuko Biol, 2006, 80 (6) ∶13451353.

[11]Nagaraj S, Ziske C, Schmidt Wolf IG, et al.Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non viral interleukin-2gene transfer[J].Genet Vaccines Ther, 2004, 2 (1) ∶12-17.

[12]Finke S, Trojaneck B, Lefterova P, et al.Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+immunologic effector cells by receptor-mediated transfection with the interleukin-7gene[J].Gene Ther, 1998, 5 (1) ∶31-39.

[13]LI hui-fang, YANG Yong-hong, Shiyongjin, et al.Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1cDNA[J].Chin Med J (Engl) , 2004, 117 (9) ∶1348-1352.

[14]Thorne SH, Negrin RS, Contag CH.Synergistic antitumor effects of immune cell-viral biotherapy[J].Science, 2006, 311 (5768) ∶1780-1784.

[15]Schmidt-Wolf IG, Lefterova P, Johnston V, et al.Sensitivity of multidrug-resistant tumor cell lines to immunologic effectorcells[J].Cell Immunol, 1996, 169 (1) ∶85-90.

[16]刘苗, 吴小艳, 金润铭.细胞因子诱导的杀伤细胞生物活性及杀瘤机制[J].实用儿科临床杂志, 2009, 24 (15) ∶1163-1166.

[17]Mehta BA, Schmidt-Wolf IG, Weissman IL, et al.Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+killer cells[J].Blood, 1995, 86 (9) ∶3493-3499.

[18]Kornacker M, Moldenhauer G, Herbst M, et al.Cytokine-induced killer cells against autologous CLL:direct cytotoxic effects and induction of immune accessory molecules by interferon gamma[J].Int J Cancer, 2006, 119 (6) ∶1377-1382.

[19]Sun S, Li XM, Li XD, et al.Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803gastric cancer cell lines[J].Cancer Biother Radiopharm, 2005, 20 (2) ∶173-180.

[20]任欢, 邢淑贤, 徐红薇, 等.CIK的体外增值及体内外杀瘤活性的实验研究[J].中国肿瘤生物治疗杂志, 1999, 6 (1) ∶17-21.

[21]陈国林, 胡怀东, 袁迪, 等.CIK细胞对裸鼠人肝癌转移预防和治疗[J].重庆医科大学学报2008, 33 (11) ∶1338-1340.

[22]Zhang YS, Yuan FJ, Jia GF, et al.CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R[J].World J Gastroenterol, 2005, 11 (22) ∶3339-3345.

[23]施明, 姚莉, 王福生, 等.人源细胞因子诱导的杀伤细胞联合化疗药物对裸鼠肝癌移植瘤的抑制作用[J].中华肿瘤杂志, 2004, 26 (8) ∶465-468.

[24]杜智, 赵邢力, 高英堂, 等.术中失血来源的树突状细胞用于肝癌治疗的体外实验研究[J].中华肿瘤杂志, 2008, 30 (10) ∶759-763.

[25]Takayama T, Sekine T, MakuuchiM, et al.Adoptive immunothera-py to lower postsurgical recurrence rates of hepatocellular carcino-ma:a randomised trial[J].Lancet, 2000, 356 (9232) ∶802-807.

[26]Ming Shi, Bing Zhang, Zi Rong, et al.Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma[J].World Gastroenterol, 2004, 10 (8) ∶1146-1151.

[27]赵明, 吴沛宏, 曾益新, 等.经肝动脉栓塞化疗序贯联合射频消融和细胞因子诱导的杀伤细胞治疗肝细胞癌的随机研究[J].中华医学杂志, 2006, 86 (26) ∶1823-1828.

[28]Weng DS, Zhou J, Zhou QM, et al.Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas[J].J Immunotherapy, 2008, 31 (1) ∶63-71.

[29]史跃, 罗中华, 孙立军, 等.肝动脉灌注细胞因子诱导杀伤细胞联合超液化碘油栓塞介入治疗原发性肝癌[J].实用放射学杂志, 2008, 24 (2) ∶231-233.

[30]Hui D, Qiang L, Jian W, et al.A randomized, controlled trial opostoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma[J].Dig Liver Dis, 2009, 41 (1) ∶36-41.

施引文献

资源附件(0)

访问统计